3 Things You Need to Know From Astex Pharmaceuticals, Inc. (ASTX)’s Q2 Earnings

Page 2 of 2

Buy, sell, or hold?
The market reacted positively to Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)’s second-quarter results, sending shares up by nearly 6%. Astex has soared more than 80% so far in 2013. Should investors be looking to buy, sell, or hold?

My take is that it probably makes sense to listen to what the company is saying about the challenges it could face next year. With that in mind, buying now might not be the best idea. If you own Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) already, you couldn’t be blamed for taking some profits off the table.

I think that Astex has solid potential to grow over the long run, though. Investors who hold their shares past 2014 could be glad that they did.

The article 3 Things You Need to Know From Astex’s Q2 Earnings originally appeared on Fool.com.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Celgene. It recommends and owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2